Drug class
Neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist; non-hormonal therapy for menopausal vasomotor symptoms
Mechanism of action
Antagonises NK1 and NK3 receptors in thermoregulatory pathways, modulating neurokinin-mediated signalling involved in menopausal vasomotor symptoms. It is not an oestrogen replacement therapy.
General use cases
- Treatment of moderate-to-severe vasomotor symptoms (hot flushes and night sweats) due to menopause under the US FDA LYNKUET indication approved in 2025
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
